



Research Article

ISSN : 0975-7384
CODEN(USA) : JCPRC5

Simultaneous determination of Ambroxal hydrochloride and Salbutamol Sulphate in pharmaceutical dosage by reverse phase high performance liquid chromatography

Rajan V. Rele

Central Research Laboratory, D. G. Ruparel College, Matunga, Mumbai, India

ABSTRACT

A simple, rapid and accurate high performance liquid chromatography method is described for simultaneous determination of ambroxal hydrochloride and salbutamol sulphate from active pharmaceutical ingredients. The separation of drug was achieved on Zorbax Eclipse C18 (250 x 4.6 mm i.d.) with 5 μ particle size column showed most favorable chromatographic pattern over the other columns. The mobile phase consisted of a mixture of buffer and acetonitrile (75:25 % v/v). The buffer was mixtures of 0.1 % (v/v) tri-ethyl amine solution adjusted the pH 3.5 with ortho-phosphoric acid. The detection was carried out at wavelength 230 nm. The mixture of buffer of pH 3.5 and acetonitrile (75:25% v/v) was used as a diluent. The method was validated for system suitability, linearity, accuracy, precision, robustness, stability of sample solution. The method has been successfully used to analyze ambroxal hydrochloride from active pharmaceutical ingredients.

Keywords: Ambroxal hydrochloride, Salbutamol sulphate, Acetonitrile, tri-ethyl amine, ortho phosphoric acid.

INTRODUCTION

Ambroxal Hydrochloride is trans-4-[(2Amino-3,5-dibromobenzyl)amino] cyclohexanol. It shows molecular formula as $C_{13}H_{18}Br_2N_2O.HCl$ with molecular weight 414.57. It is official in BP [1] and IP [2]. Ambroxal is a metabolite of bromhexine. It is an expectoration improver and mucolytic agent used in the treatment of acute and chronic disorders characterized by the production of excess or thick mucus.

Salbutamol sulphate is, chemically known as bis [(1RS)-2-[(1, 1-Di-methyl-ethyl) amino]-1-[4-hydroxy-3-(hydroxyl methyl) phenyl] ethanol] sulphate, is beta-adrenoceptor agonist used for the relief of broncho-spasm in conditions such as asthma and chronic obstructive pulmonary disease. The drug is official in Indian pharmacopoeia [2]. Literature survey reveals UV spectrophotometric [3] and HPLC [4-6] for simultaneous determination of ambroxal hydrochloride and salbutamol sulphate in combined dosage form. Combination of ambroxal hydrochloride and salbutamol sulphate is used for the treatment of asthma and bronchitis.

EXPERIMENTAL SECTION

Chemical and reagents

Reference standard of ambroxal hydrochloride was obtained from reputed firm with certificate of analysis. Tri-ethylamine, acetonitrile and ortho phosphoric acid were used of analytical grade and the HPLC grade water was

used from Millipore. Standard and sample solutions were prepared in diluent [mixture of buffer of pH 3.5 and acetonitrile (75:25 % v/v)].

Instrumentation

The HPLC system used was MERCK Hitachi HPLC system equipped with auto sampler (D 7200 separation module) and UV detector (D- 7400). The chromatogram was recorded and peaks quantified by means of PC based EZ Chrom Elite software. A SHIMADZU analytical balance (0.01 mg) was used.

Preparation of Standard preparation

Standard solution

A 30 mg of standard ambroxal hydrochloride and 2 mg of salbutamol sulphate were weighted accurately and transferred in 10 ml volumetric flask. About 5 ml of diluent [mixture of buffer of pH 3.5 and acetonitrile (75:25 % v/v)] was added and sonicated for 10 minutes. The volume was adjusted up to the mark with diluent to give concentration as 300 µg /ml of ambroxal hydrochloride and 20 µg /ml of salbutamol sulphate respectively. The working standard solution was prepared by diluting 1 ml of 300 µg /ml of ambroxal hydrochloride and 20 µg /ml. of salbutamol sulphate solution to 10 ml with diluent to get concentration 30 µg /ml of ambroxal hydrochloride and 2 µg /ml of salbutamol sulphate respectively.


Sample preparation

Twenty tablets were weighed accurately and average weight of each tablet was determined. A powder equivalent to 30 mg of standard ambroxal hydrochloride and 2 mg of salbutamol sulphate were weighted accurately and transferred in 10 ml volumetric flask to give concentration as 300 µg /ml of ambroxal hydrochloride and 20 µg /ml. of salbutamol sulphate respectively. The working standard solution was prepared by diluting 1 ml of 300 µg /ml of ambroxal hydrochloride and 20 µg /ml of salbutamol sulphate solution to 10 ml with diluent to get concentration 30 µg /ml of ambroxal hydrochloride and 2 µg /ml. of salbutamol sulphate respectively.

Chromatographic condition

Chromatographic separation was performed at ambient temperature on a reverse phase Zorbax Eclipse C18 (250 x 4.6 mm i.d.) with 5 µ particle size column. The mobile phase was a mixture of buffer of pH 3.5 and acetonitrile (75:25 % v/v). The buffer was mixtures of 0.1 % (v/v) tri-ethyl amine adjusted the pH 3.5 with ortho-phosphoric acid. The flow rate of the mobile phase was adjusted to 1 ml /min. The detection was carried out at wavelength 230 nm. (Fig.1) The injection volume of the standard and sample solution was set at 1.0 µl.

Figure 1: Overlay UV spectra of ambroxal hydrochloride and salbutamol sulphate



Method validation

System suitability

System performances of developed HPLC method were determined by injecting standard solutions. Parameter such as theoretical plates (N), symmetry, and area were determined. The results are shown in table 1 which indicates good performance of the system.

Table 1: System suitability parameters evaluated on standard solution of Ambroxal hydrochloride and salbutamol sulphate

Name	Retention Time	Area	Area %	USP Plate Count	Symmetry	Resolution
Salbutamol sulphate	2.330	1181710	7.70	1862	1.87	-
Ambroxal hydrochloride	5.727	14172249	92.30	2501	1.79	10.08

Specificity

Specificity is the ability of the method to resolve the active ingredients. Hence blank, standard ambroxal hydrochloride was injected to prove specificity. The typical chromatogram of the standard and sample assayed are given in figure 2 and 3 respectively.

Figure 2: Typical chromatogram of ambroxal hydrochloride (standard)





Figure 3: Typical chromatogram of ambroxal hydrochloride (sample)



Linearity

Under the experimental conditions described above, linear calibration curve were obtained throughout the concentration range studied. Regression analysis was done on the peak area (y) v/s concentration (x). The regression analysis data obtained is tabulated in table no. 2.

Table 2: Statistical evaluation of the data subjected to regression analysis

Parameters	Ambroxal hydrochloride	Salbutamol sulphate
Correlation Coefficient (r)	0.9999	0.9998
% Intercept (y)	98232	7223.7
Slope (m)	46279	54417

Accuracy

The accuracy method was determined by applying proposed method to synthetic mixture containing known amount of drug corresponding to 80 %, 100 % and 120 %. The accuracy was then calculated as the percentage of analyte recovered by the assay. The results of the recovery analysis are enclosed under table no.3, 4.

Table 3: Statistical evaluation of the data subjected to accuracy of ambroxal hydrochloride

level	test	wt in mg	area	quantity added in $\mu\text{g/ml}$	quantity recovered in $\mu\text{g/ml}$	% recovery	mean recovery
80%	1	30.41	11391609	244.08	242.76	99.46	99.60
	2	30.52	11389611	244.08	242.72	99.44	
	3	30.45	11441107	244.08	243.82	99.89	
100%	1	30.46	14242955	305.1	303.52	99.48	99.26
	2	30.49	14246540	305.1	303.60	99.51	
	3	30.51	14143747	305.1	301.41	98.79	
120%	1	30.52	17036850	366.12	363.06	99.17	99.27
	2	30.50	17033316	366.12	362.99	99.14	
	3	30.49	17092315	366.12	364.25	99.49	
Mean recovery of all level							99.37

Table 4 : Statistical evaluation of the data subjected to accuracy of salbutamol sulphate

level	test	wt in mg	area	quantity added in $\mu\text{g/ml}$	quantity recovered in $\mu\text{g/ml}$	% recovery	mean recovery
80%	1	2.1	947898	16.88	16.79	99.44	99.42
	2	2.12	948747	16.88	16.80	99.53	
	3	2.14	946267	16.88	16.76	99.27	
100%	1	2.13	1182252	21.1	20.94	99.22	98.96
	2	2.09	1183567	21.1	20.96	99.33	
	3	2.12	1171612	21.1	20.75	98.33	
120%	1	2.11	1422848	25.32	25.20	99.51	99.57
	2	2.13	1421150	25.32	25.17	99.39	
	3	2.11	1426835	25.32	25.27	99.79	
Mean recovery of all level							99.31

Precision

The method precision was established by carrying out the analysis of ambroxal hydrochloride. The assay was carried out of the drug using analytical method in five replicates. The value of relative standard deviation lies well with the limits. The results of the same are tabulated in the table no. 4, 5.

Table 4: Statistical evaluation of the data subjected to method precision of ambroxal hydrochloride

Test	wt of test	Area	% assay
Test -1	30.20	14165713	99.99
Test -2	30.21	14163541	99.94
Test -3	30.61	14386548	100.19
Test -4	30.69	14388271	99.94
Test -5	30.46	14382678	100.66
Test -6	30.55	14380721	100.35
Mean Assay			100.18
SD			0.284
RSD			0.284

Table 5: Statistical evaluation of the data subjected to method precision of salbutamol sulphate

Test	wt of test	Area	% assay
Test -1	2.09	1177766	99.79
Test -2	2.08	1174252	99.97
Test -3	2.13	1190320	98.96
Test -4	2.10	1193420	100.64
Test -5	2.13	1195231	99.37
Test -6	2.12	1191704	99.54
Mean Assay			99.71
SD			0.572
RSD			0.574

Robustness

The robustness of the method was determined to check the reliability of an analysis with respect to deliberate variations in method parameters.

The typical variations are given below:

Variation in the flow rate by ± 0.2 ml /min

Variation in mobile phase composition by ± 2 %

Variation in wavelength ± 5 nm

The results of the analysis of the samples under the conditions of the above variation indicated the nature of robustness of the method.

Method application

Twenty tablets were weighed accurately and average weight of each tablet was determined. A powder equivalent to 30 mg of standard ambroxal hydrochloride and 2 mg of salbutamol sulphate were weighed accurately and transferred in 10 ml volumetric flask to give concentration as 300 μg /ml of ambroxal hydrochloride and 20 μg /ml. of salbutamol sulphate respectively. The working standard solution was prepared by diluting 1 ml of 300 μg /ml of ambroxal hydrochloride and 20 μg /ml. of salbutamol sulphate solution to 10 ml with diluent to get concentration 30 μg /ml of ambroxal hydrochloride and 100 μg /ml. of salbutamol sulphate respectively. From this solution 1.0 μl was injected specific conditions. The analyte peak was identified by comparison with that of respective standard. The (%) assay results were expressed in table no. 4, 5. It indicates the amount of ambroxal hydrochloride and salbutamol sulphate in the product meets the requirement.

RESULTS AND CONCLUSION

The reproducibility, repeatability and accuracy of the proposed method were found to be satisfactory which is evidenced by low values of standard deviation and percent relative standard deviation. The accuracy and reproducibility of the proposed method was confirmed by recovery experiments, performed by adding known amount of the drug to the pre-analyzed active pharmaceutical ingredient and reanalyzing the mixture by proposed method. Thus the proposed RP-HPLC method is used for estimation of ambroxal hydrochloride and salbutamol sulphate from active pharmaceutical ingredient. It is more precise, accurate, linear, robust, simple and rapid method. Hence the proposed RP-HPLC method is strongly recommended for the quality control of the raw material, active pharmaceutical ingredient and pharmaceutical formulation.

Acknowledgment

Authors express sincere thanks to the principal, Dr. Tushar M. Desai, of D.G. Ruparel College, Mumbai for encouragement and providing laboratory facilities.

REFERENCES

- [1] British Pharmacopoeia, Her Majesty's Stationary Office, London, **2010**, Volume I, II, and III.
- [2] Indian Pharmacopoeia, Controller of Publication, Delhi, **2010** volume I, II, III.2224.
- [3] P.A. Patel, M.N. Dole; P.S.; Shedpure, S.D. Sawan.; *Asian Journal of Pharmaceutical and Clinical Research*, **2011**, 4(3) , 42-45.
- [4] Avinash V. Deosarkar; Shruti D. Deshpande; Sanjay G.Walode; Deepali S.Tuljapure; Sainath G. Tekale; Vijay M. Waghmode, *International Journal of Pharmacy and Pharmaceutical Sciences*, **2012** , 4 (1 4), 307-311.
- [5] V. SriKalyani, D.; Meena Bharathi; M. Anusha, B.; Chandra Priyanka ; Buchi N. Nalluri, *Journal of chemical and pharmaceutical research*, **2013**, 5(11),443-449.
- [6] Parag G Bhortake ; Rama S Lokhande, *International journal of pharma research and health sciences*, **2014**, 2 (6), 408-412.